Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer

Pancreatology

Volumn 16, Issue 2, 2016, Pages 249-258

  Ciliberto, Domenico ^a   Staropoli, Nicoletta ^a   Chiellino, Silvia ^a   Botta, Cirino ^a   Tassone, Pierfrancesco ^a   Tagliaferri, Pierosandro ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Advanced pancreatic cancer; Meta analysis; Pancreatic cancer; Pathway; Randomized clinical trials; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; HAZARD RATIO; HUMAN; META ANALYSIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84956645014     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2016.01.003     Document Type: Article

References (72)

1. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, and et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 2015 E359 E386
2. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
3. M. Malvezzi, P. Bertuccio, F. Levi, C. La Vecchia, and E. Negri European cancer mortality predictions for the year 2014 Ann Oncol Off J Eur Soc Med Oncol/ESMO 25 2014 1650 1656
4. A. Vincent, J. Herman, R. Schulick, R.H. Hruban, and M. Goggins Pancreatic cancer Lancet 378 2011 607 620
5. D.P. Ryan, T.S. Hong, and N. Bardeesy Pancreatic adenocarcinoma N Engl J Med 371 2014 2140 2141
6. A. Sultana, C.T. Smith, D. Cunningham, N. Starling, J.P. Neoptolemos, and P. Ghaneh Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer J Clin Oncol Off J Am Soc Clin Oncol 25 2007 2607 2615
7. H.A. Burris 3rd, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, and et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol Off J Am Soc Clin Oncol 15 1997 2403 2413
8. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, Y. Becouarn, and et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer N Engl J Med 2011 1817-1825 364
9. C. Louvet, R. Labianca, P. Hammel, G. Lledo, M.G. Zampino, T. Andre, and et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol Off J Am Soc Clin Oncol 23 2005 3509 3516
10. D. Cunningham, I. Chau, D.D. Stocken, J.W. Valle, D. Smith, W. Steward, and et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol Off J Am Soc Clin Oncol 27 2009 5513 5518
11. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, and et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 2013 1691 1703
12. D. Ciliberto, C. Botta, P. Correale, M. Rossi, M. Caraglia, P. Tassone, and et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials Eur J cancer 49 2013 593 603
13. I. Gounaris, K. Zaki, and P. Corrie Options for the treatment of gemcitabine-resistant advanced pancreatic cancer JOP J Pancreas 11 2010 113 123
14. H. Burris 3rd, and C. Rocha-Lima New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways Oncologist 13 2008 289 298
15. J.P. Morton, and B.C. Lewis Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle 6 2007 1553 1557
16. A.S. Strimpakos, K.N. Syrigos, and M.W. Saif The molecular targets for the diagnosis and treatment of pancreatic cancer Gut Liver 4 2010 433 449
17. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, S. Gallinger, and et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group J Clin Oncol Off J Am Soc Clin Oncol 25 2007 1960 1966
18. H.L. Kindler, D. Niedzwiecki, D. Hollis, S. Sutherland, D. Schrag, H. Hurwitz, and et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and Leukemia Group B (CALGB 80303) J Clin Oncol Off J Am Soc Clin Oncol 28 2010 3617 3622
19. B.M. Wolpin, A.F. Hezel, T. Abrams, L.S. Blaszkowsky, J.A. Meyerhardt, J.A. Chan, and et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer J Clin Oncol Off J Am Soc Clin Oncol 27 2009 193 198
20. E.J. Kim, V. Sahai, E.V. Abel, K.A. Griffith, J.K. Greenson, N. Takebe, and et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma Clin Cancer Res Off J Am Assoc Cancer Res 20 2014 5937 5945
21. L.A. Stewart, M.K. Parmar, and J.F. Tierney Meta-analyses and large randomized, controlled trials N Engl J Med 338 61 1998 author reply 61-62
22. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
23. M.K. Parmar, L.A. Stewart, and D.G. Altman Meta-analyses of randomised trials: when the whole is more than just the sum of the parts Br J Cancer 74 1996 496 501
24. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, and et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
25. D. Moher, D.G. Altman, A. Liberati, and J. Tetzlaff PRISMA statement Epidemiology 22 2011 128 author reply 128
26. S. Armijo-Olivo, C.R. Stiles, N.A. Hagen, P.D. Biondo, and G.G. Cummings Assessment of study quality for systematic reviews: a comparison of the Cochrane collaboration risk of bias tool and the effective public health practice project quality assessment tool: methodological research J Eval Clin Pract 18 2012 12 18
27. A.S. Detsky, C.D. Naylor, K. O'Rourke, A.J. McGeer, and K.A. L'Abbe Incorporating variations in the quality of individual randomized trials into meta-analysis J Clin Epidemiol 45 1992 255 265
28. M. Crowther, W. Lim, and M.A. Crowther Systematic review and meta-analysis methodology Blood 116 2010 3140 3146
29. D. Wang, Z.Y. Mou, J.X. Zhai, H.X. Zong, and X.D. Zhao Application of Stata software to test heterogeneity in meta-analysis method Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 29 2008 726 729
30. R. DerSimonian, and R.J. Levine Resolving discrepancies between a meta-analysis and a subsequent large controlled trial JAMA J Am Med Assoc 282 1999 664 670
31. R. DerSimonian, and R. Kacker Random-effects model for meta-analysis of clinical trials: an update Contemp Clin Trials 28 2007 105 114
32. J.A. Sterne, A.J. Sutton, J.P. Ioannidis, N. Terrin, D.R. Jones, J. Lau, and et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials BMJ 343 2011 d4002
33. R.C. Boston, and A.E. Sumner Stata: a statistical analysis system for examining biomedical data Adv Exp Med Biol 537 2003 353 369
34. H.L. Kindler, D.A. Richards, L.E. Garbo, E.B. Garon, J.J. Stephenson Jr., C.M. Rocha-Lima, and et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer Ann Oncol Off J Eur Soc Med Oncol/ESMO 23 2012 2834 2842
35. V. Heinemann, M.P. Ebert, R.P. Laubender, P. Bevan, C. Mala, and S. Boeck Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer Br J Cancer 108 2013 766 770
36. G. Middleton, P. Silcocks, T. Cox, J. Valle, J. Wadsley, D. Propper, and et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial Lancet Oncol 15 2014 829 840
37. C.S. Fuchs, S. Azevedo, T. Okusaka, J.L. Van Laethem, L.R. Lipton, H. Riess, and et al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the gamma trialdagger Ann Oncol Off J Eur Soc Med Oncol/ESMO 26 2015 921 927
38. M. Reni, S. Cereda, M. Milella, A. Novarino, A. Passardi, A. Mambrini, and et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial Eur J Cancer 49 2013 3609 3615
39. P.A. Philip, J. Benedetti, C.L. Corless, R. Wong, E.M. O'Reilly, P.J. Flynn, and et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial s0205 J Clin Oncol Off J Am Soc Clin Oncol 28 2010 3605 3610
40. H.L. Kindler, T. Ioka, D.J. Richel, J. Bennouna, R. Letourneau, T. Okusaka, and et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study Lancet Oncol 12 2011 256 262
41. J.P. Spano, C. Chodkiewicz, J. Maurel, R. Wong, H. Wasan, C. Barone, and et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study Lancet 371 2008 2101 2108
42. D.A. Richards, P.R. Kuefler, C. Becerra, L.S. Wilfong, R.H. Gersh, K.A. Boehm, and et al. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study Investig New Drugs 29 2011 144 153
43. A. Goncalves, M. Gilabert, E. Francois, L. Dahan, H. Perrier, R. Lamy, and et al. Baypan study: a double-blind phase iii randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer Ann Oncol Off J Eur Soc Med Oncol/ESMO 23 2012 2799 2805
44. B.M. Wolpin, E.M. O'Reilly, Y.J. Ko, L.S. Blaszkowsky, M. Rarick, C.M. Rocha-Lima, and et al. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer Ann Oncol Off J Eur Soc Med Oncol/ESMO 24 2013 1792 1801
45. A.M. Senderowicz, J.R. Johnson, R. Sridhara, P. Zimmerman, R. Justice, and R. Pazdur Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas Oncol Willist Park 21 2007 1696 1706 discussion 1706-1699, 1712, 1715
46. S.G. Eckhardt, P. De Porre, D. Smith, J. Maurel, W.P. Steward, O. Bouche, and et al. Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer J Pain Symptom Manag 37 2009 135 143
47. P. Rougier, H. Riess, R. Manges, P. Karasek, Y. Humblet, C. Barone, and et al. Randomised, placebo-controlled, double-blind, parallel-group phase iii study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer Eur J cancer 49 2013 2633 2642
48. P.A. Philip, B. Goldman, R.K. Ramanathan, H.J. Lenz, A.M. Lowy, R.P. Whitehead, and et al. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727) Cancer 120 2014 2980 2985
49. S. Cascinu, R. Berardi, A. Sobrero, P. Bidoli, R. Labianca, S. Siena, and et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a GISCAD randomized phase ii study Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 46 2014 182 186
50. D. Propper, I. Davidenko, J. Bridgewater, L. Kupcinskas, A. Fittipaldo, C. Hillenbach, and et al. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma Ann Oncol Off J Eur Soc Med Oncol/ESMO 25 2014 1384 1390
51. J.R. Infante, B.G. Somer, J.O. Park, C.P. Li, M.E. Scheulen, S.M. Kasubhai, and et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas Eur J Cancer 50 2014 2072 2081
52. J.Y. Hong, E.M. Nam, J. Lee, J.O. Park, S.C. Lee, S.Y. Song, and et al. Randomized double-blinded, placebo-controlled phase ii trial of simvastatin and gemcitabine in advanced pancreatic cancer patients Cancer Chemother Pharmacol 73 2014 125 130
53. H. Yamaue, T. Tsunoda, M. Tani, M. Miyazawa, K. Yamao, N. Mizuno, and et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer; PEGASUS-PC study Cancer Sci. 106 7 2015 883 890
54. L. Bergmann, L. Maute, G. Heil, J. Russel, E. Weidmann, D. Koberle, and et al. A prospective randomised phase-ii trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the Cesar Central European Society for Anticancer Drug Research-EWIV Eur J Cancer 51 2015 27 36
55. E. Van Cutsem, M. Hidalgo, I. Bazin, J.-L. Canon, E. Poddubskaya, N. Manojlovic, and et al. Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer ASCO Meet Abstr 33 2015 344
56. A.J. Scott, B.H. O'Neil, C. Gomes, J.C. Baranda, S.J. Cohen, M.A. Tejani, and et al. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer ASCO Meet Abstr 33 2015 342
57. G. Deplanque, M. Demarchi, M. Hebbar, P.J. Flynn, B. Melichar, J. Atkins, and et al. Masitinib in nonresectable pancreatic cancer: results of a phase iii randomized placebo-controlled trial ASCO Meet Abstr 31 2013 158
58. A.G. Dalgleish The IMAGE I Trial Investigators: a multicenter randomized, open-label, proof-of-concept, phase ii trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer ASCO Meet Abstr 33 2015 336
59. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, and et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
60. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, and et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
61. Q. Li, Z. Yuan, H. Yan, Z. Wen, R. Zhang, and B. Cao Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer Clin Ther 36 2014 1054 1063
62. L. Faloppi, K. Andrikou, C. Loretelli, A. Mandolesi, M. Bianconi, M. Scartozzi, and et al. Locally advanced or metastatic pancreatic tumors: molecular biology may help to know it and to select the optimal treatment ASCO Meet Abstr 31 2013 201
63. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
64. C.E. Clark, G.L. Beatty, and R.H. Vonderheide Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer Cancer Lett 279 2009 1 7
65. A.H. Ko Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities J Clin Oncol Off J Am Soc Clin Oncol 33 2015 1779 1786
66. C. Botta, A. Gulla, P. Correale, P. Tagliaferri, and P. Tassone Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities Front Oncol 4 2014 348
67. C. Arslan, and S. Yalcin Current and future systemic treatment options in metastatic pancreatic cancer J Gastrointest Oncol 5 2014 280 295
68. S. Haider, J. Wang, A. Nagano, A. Desai, P. Arumugam, L. Dumartin, and et al. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma Genome Med 6 2014 105
69. E.A. Collisson, A. Sadanandam, P. Olson, W.J. Gibb, M. Truitt, S. Gu, and et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy Nat Med 17 2011 500 503
70. A. Wang-Gillam, T.M. Nywening, D.E. Sanford, A.C. Lockhart, R. Suresh, B.R. Tan, and et al. Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC) ASCO Meet Abstr 33 2015 338
71. A. De Jesus-Acosta, P.J. O'Dwyer, R.K. Ramanathan, D.D. Von Hoff, A. Maitra, Z. Rasheed, and et al. A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA) ASCO Meet Abstr 32 2014 257
72. L. Chen, M. Zhang, and S. Luo Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase iii studies Tumour Biol J Int Soc Oncodev Biol Med 35 2014 11551 11558